Login
$ANRO
$27.12 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Amit Etkin Also a director
Chief Executive Officer
49 Not stated $2,188,487
Nicholas Smith
PRESIDENT AND CFO
Title from the Form 4 dated Oct 2, 2026
37 Not stated $1,541,585
Michael Hanley
Chief Operating Officer
53 Since 2024
2 years
$1,212,928
Adam Savitz
Chief Medical Officer
60 Since 2021
5 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Mar 26, 2026 · updated by the 8-K of May 28, 2026

Directors
7
serving now
Independent
0 of 1
stated in the proxy; 6 not stated
Average tenure
3.7 years
from year joined
CEO also chairs the board
Yes
Amit Etkin, M.D., Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Amit Etkin, M.D., Ph.D.
49 2019
7 years
Not independent None stated None stated Paid as CEO
Christopher Nixon Cox
47 2022
4 years
Not stated
Audit
High-Trend International Group (Nasdaq: HTCO) $110,543
Raymond Sanchez, M.D.
65 2025
1 year
Not stated None stated Rapport Therapeutics, Inc. (Nasdaq: RAPP) $84,904
Gwill York
69 2021
5 years
Not stated None stated Sofina SA $88,178
Andrew Dreyfus
67 2023
3 years
Not stated
Audit
None stated $80,263
Husseini Manji, M.D.
67 2024
2 years
Not stated None stated None stated $73,129
Andrew Miller Joined May 27, 2026
- - - - - -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

Entities affiliated with Steven A. Cohen
Beneficially own greater than 5% of our capital stock following the IPO
16,400,000
February 2024

Purchased 1,025,000 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Alpha Wave Ventures II, LP
Beneficially owns greater than 5% of our capital stock; Chris Dimitropoulos, a former member of our Board, is a Managing Director of Alpha Wave Global LP
9,600,000
February 2024

Purchased 600,000 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Entities affiliated with InVivium Capital
Michael Liang, Ph.D., a former member of our Board, is Managing Partner of InVivium Capital
900,000
February 2024

Purchased 56,250 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz
Beneficiary is the spouse of Adam Savitz, our Chief Medical Officer
272,000
February 2024

Purchased 17,000 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Robert L. Friedman 2003 Long-Term Trust fbo Andrew Friedman
Beneficiary is the brother-in-law of Adam Savitz, our Chief Medical Officer
272,000
February 2024

Purchased 17,000 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Amit Etkin, M.D., Ph.D.
President, Chief Executive Officer and Chair of our Board
50,000
February 2024

Purchased 3,125 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Dan Segal
Beneficially owned greater than 5% of our capital stock prior to the IPO closing; previously served as a member of our Board
25,008
February 2024

Purchased 1,563 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Nicholas Smith
25,008
February 2024

Purchased 1,563 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Oran Etkin
Sibling of Amit Etkin, M.D., Ph.D., our President, Chief Executive Officer and Chair of our Board
15,008
February 2024

Purchased 938 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Alison Savitz & David Glass
Alison Savitz is the sibling of Adam Savitz, our Chief Medical Officer
10,000
February 2024

Purchased 625 shares of common stock in the IPO directed share program at $16.00 per share

With underwriters Open in proxy
Entities associated with Perceptive Advisors
Beneficial owner of greater than 5% of our capital stock
14,999,744
2025

Purchased 2,536,354 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement

With the Company Open in proxy
Commodore Capital Master LP
Beneficial owner of greater than 5% of our capital stock
14,999,844
2025

Purchased 1,000,000 shares of common stock and 1,536,354 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement

With the Company Open in proxy
Entities associated with Vestal Point Capital, LP
Beneficial owner of greater than 5% of our capital stock
9,500,001
2025

Purchased 1,606,358 shares of common stock in the 2025 private placement

With the Company Open in proxy
Entities associated with Point72 Asset Management
Beneficial owner of greater than 5% of our capital stock
6,499,946
2025

Purchased 549,544 shares of common stock and 549,543 shares issuable upon exercise of Pre-Funded Warrants in the 2025 private placement

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support